Rap1-Rac1 Circuits Potentiate Platelet Activation by Stefanini, L. et al.
Rap1-Rac1 Circuits Potentiate Platelet Activation
Lucia Stefanini, Yacine Boulaftali, Timothy D. Ouellette, Michael Holinstat, Laurent Désiré,
Bertrand Leblond, Patrick Andre, Pamela B. Conley, and Wolfgang Bergmeier
Cardeza Foundation for Hematologic Research and Department of Medicine (L.S., Y.B., T.D.O.,
M.H., W.B.), Thomas Jefferson University, Philadelphia, PA; McAllister Heart Institute (L.S., Y.B.,
T.D.O., W.B.), and Department of Biochemistry and Biophysics (W.B.), University of North
Carolina at Chapel Hill, Chapel Hill, NC; ExonHit Therapeutics (L.D., B.L.), Therapeutic Division,
Paris, France; Portola Pharmaceuticals (P.A., P.B.C.), South San Francisco, CA
Abstract
Objective—The goal of this study was to investigate the potential crosstalk between Rap1 and
Rac1, 2 small GTPases central to platelet activation, particularly downstream of the collagen
receptor GPVI.
Methods and Results—We compared the activation response of platelets with impaired Rap
signaling (double knock-out; deficient in both the guanine nucleotide exchange factor, CalDAG-
GEFI, and the Gi-coupled receptor for ADP, P2Y12), to that of wild-type platelets treated with a
novel Rac inhibitor, EHT 1864 (wild-type/EHT). We found that Rac1 is sequentially activated
downstream of Rap1 on stimulation via GPVI. In return, Rac1 provides important feedback for
both CalDAG-GEFI– and P2Y12-dependent activation of Rap1. When analyzing platelet
responses controlled by Rac1, we observed (1) impaired lamellipodia formation, clot retraction,
and granule release in both double knock-out and wild-type/EHT platelets; and (2) reduced
calcium store release in wild-type/EHT but not double knock-out platelets. Consistent with the
latter finding, we identified 2 pools of Rac1, 1 activated immediately downstream of GPVI and 1
activated downstream of Rap1.
Conclusion—We demonstrate important crosstalk between Rap1 and Rac1 downstream of
GPVI. Whereas Rap1 signaling directly controls sustained Rac1 activation, Rac1 affects CalDAG-
GEFI– and P2Y12-dependent Rap1 activation via its role in calcium mobilization and granule/
ADP release, respectively.
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Platelet activation results in a series of rapid morphological events that depend on actin and
are a common feature of all cell-based clotting systems across evolution. Rearrangements of
the actin cytoskeleton are crucial for shape change, platelet-substrate (spreading) and
platelet-platelet (aggregation) interactions, and granule secretion.1
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The small GTPases of the Ras2 and Rho3 families are critical regulators of cellular
activation. Small GTPases are molecular switches cycling between a GTP-bound state, able
to interact with effector molecules and to initiate downstream responses, and a GDP-bound
state. They are tightly regulated by guanine nucleotide exchange factors (GEFs), that
accelerate the rate-limiting dissociation of GDP, and guanine nucleotidase-activating
proteins, that promote the intrinsic GTPase activity and terminate signal transduction.4
RhoA, Cdc42, and Rac1, prototypical members of the Rho family, are the main regulators of
actin remodeling in cells.5 Although RhoA regulates the formation of stress fibers and focal
adhesion contacts,6 Cdc42 promotes the formation of filopodial protrusions.7 Rac induces
the formation of sheet-like lamellipodial protrusions8 and participates in exocytosis.9
Independently of actin dynamics, Rac regulates phospholipase Cγ2 (PLCγ2) activation,10
ROS generation, transcription, MAPK signaling, and cell proliferation.3 In mammals there
are 3 Rac isoforms, but only Rac1 was detected at the protein level in platelets.11 Recent
studies with knockout mouse models and small molecule inhibitors have shown that Rac1 is
essential for lamellipodia formation, granule secretion, clot retraction, and PLCγ2 activation
in platelets.11–16 Because of its role in PLCγ2 activation, Rac1 deficient platelets are
severely impaired in their response to stimulation via immunoreceptor tyrosine activation
motif (ITAM)-coupled receptors, such as the collagen receptor glycoprotein (GP) VI,16 or
the hemITAM receptor C-type lectin-like receptor 2 (CLEC-2).17
Within the Ras family, Rap GTPases are most recognized for their role in integrin
activation, the regulation of cell-cell contacts, the establishment of cell polarity and the
control of exocytosis.2,18,19 In mammals, the Rap family consists of 2 rap1 genes and 3 rap2
genes encoding proteins that are approximately 65% homologous. Platelets express
significant amounts of Rap1B and Rap2B, with Rap1B accounting for approximately 90%
of the total Rap protein.20 Loss of Rap1B inhibits integrin αIIbβ3 activation and platelet
spreading on fibrinogen, and it impairs collagen-induced dense granule secretion.21 In our
recent work, we established a 2-pathway model for Rap1-activation in platelets: 1 pathway
triggered by calcium and mediated by the guanine nucleotide exchange factor, CalDAG-
GEFI, and a CalDAG-GEFI–independent pathway that requires granule release and
cosignaling via the Gi-coupled receptor for ADP, P2Y12.22–24 Blocking of both pathways
simultaneously results in inhibition of Rap1 activation, integrin activation, granule
secretion22,25 and thromboxane A2 generation.23
Interestingly, there is growing evidence of cooperation between Rap1 and Rac1 signaling
during cellular activation.26 For example, they are both necessary to form lamellipodial
protrusions in migrating fibroblasts,27 and they regulate the cytoskeleton dynamics required
for the exocytotic process in pancreatic acinar cells.28 In platelets, both Ca2+-dependent and
Gαi signaling pathways affect Rac1 activation.29,30 Thus, the same pathways that regulate
Rap1 activation seem to control the activation of Rac1.
In the present study, we investigated the hypothesis that Rac1 in platelets is under the
control of Rap1. Using transgenic mice with impaired Rap signaling in combination with a
novel inhibitor to Rac1, we found that (1) downstream of the ITAM-coupled receptor,
GPVI, Rap1, and Rac1 facilitate optimal platelet activation by providing crucial feedback
activation for each other, and (2) there are at least 2 (temporally) distinct pools of Rac1, with
only 1 of them controlled by Rap1.
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See the Supplemental Material, available online at http://atvb.ahajournals.org, for an
exhaustive list of the materials used.
Mice
CalDAG-GEFI–/– × P2Y12–/– mice were obtained from the intercross of CalDAG-
GEFI–/–25 and P2Y12–/–31 mice. Experimental procedures were approved by the Animal
Care and Use Committee of Thomas Jefferson University.
Platelet Preparation
Blood was drawn from the retro-orbital plexus into heparinized tubes. Platelet-rich plasma
(PRP) or washed platelets were prepared as described previously.23 See Supplemental
Methods, available online at http://atvb.ahajournals.org, for details.
Small-GTPase Activation Assays
Rap1, Rap2, and Rac1 activation were determined by pull-down assay followed by standard
Western blotting procedures as described previously.23 Rac1-GTP was also quantified with
the Rac G-LISATM (Absorbance Based) Biochem kit (Cytoskeleton, Denver, CO) according
to the manufacturer instructions. See Supplemental Methods for details.
Spreading Assay
Spreading of platelets on fibrinogen in the presence or absence of the GPVI agonist
convulxin (Cvx) was performed as described in Supplemental Methods.
Platelet Clot Retraction
Washed murine platelets were resuspended in citrated human platelet-poor plasma (4×108
platelets/mL) and 150 μmol/L EHT 1864 or DMSO were added. Coagulation was triggered
by addition of thrombin (0.4 U/mL). Clots were allowed to retract at 37°C for 1 hour. The
extent of clot retraction was determined as the volume of serum extruded from the clot and
expressed as percentage of the total reaction volume.
Dense Granule Secretion
The release of 3H-serotonin into platelet supernatants after 10 minutes of stimulation was
measured as described previously.23 See Supplemental Methods for further details.
Flow Cytometry
αIIbβ3 Activation and α-Granule Secretion—Washed platelets diluted in Tyrode’s
buffer containing 0.35% BSA and 1 mmol/L CaCl2 (108 platelets/mL) were stimulated for
10 minutes with increasing doses of Cvx, costained with JON/A-PE32 (Emfret Analytics,
Wuerzburg, Germany) and α-P-selectin-FITC (BD Biosciences, Rockville, MD) for 10
minutes and immediately analyzed by flow cytometry.
Calcium Flux Measurement—Washed platelets were incubated with 5 μmol/L Fluo-4
(Invitrogen, Carlsbad, CA) for 15 minutes, diluted in Tyrode’s buffer (108 platelets/mL)
containing 2.5 mmol/L EDTA, activated with Cvx, and analyzed for fluorescence 1 intensity
over a period of 3 minutes.
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Performed as described previously.23 See Supplemental Methods for details.
Statistics
Results are reported as mean±SD and statistical significance was assessed by unpaired 2-
tailed Student t-test. A probability value less than 0.05 was considered significant.
Results
The small GTPases Rap1 and Rac1 are critical players in platelet activation, in particular
downstream of the collagen receptor GPVI. Studies in other cell systems suggest a crosstalk
between Rap1 and Rac1 during cellular activation. In this study, we sought to investigate
whether Rap1-Rac1 circuits regulate platelet activation.
In a first step, we evaluated the effect of impaired Rap1 signaling on the activation of Rac1
in platelets stimulated with Cvx, a snake venom toxin that specifically targets the collagen
receptor GPVI (Figure 1). In WT platelets, activation of both Rap1 and Rac1 was stronger at
t=1 minute than at t=10 minutes after addition of Cvx. Deficiency in CalDAG-GEFI
markedly reduced the activation of Rap1 and Rac1 at t=1 minute, while little effect was
observed at t=10 minutes. In contrast, inhibition of P2Y12×2-MesAMP reduced Rap1 and
Rac1 activation both in the early and the late phase of activation. Virtually complete
inhibition of Rap1 and Rac1 activation at t=1 minute and t=10 minutes was observed in 2-
MesAMP-treated CalDAG-GEFI–/– platelets, demonstrating a strong correlation between
the activation of Rap1 and Rac1 in platelets activated via GPVI (Figure 1A, B). To eliminate
any off-target effects of 2-MesAMP,33 we studied the activation of Rap1 and Rac1 in
platelets isolated from mice deficient in CalDAG-GEFI and P2Y12 (double knock-out,
DKO) (Figure 1C, D). Consistent with the studies using 2-MesAMP to block P2Y12, we
observed virtually complete inhibition of Rap1 and Rac1 activation in Cvx-activated DKO
platelets, both at t=1′ and 10′ after addition of the agonist. Importantly, inhibition of αIIbβ3
integrin with a monoclonal antibody during the activation process did not markedly affect
Rac1 activation in WT platelets (Supplemental Figure 1, available online at
http://atvb.ahajournals.org), demonstrating that the contribution of Rap1 to Rac1 activation
is not secondary to Rap1-mediated integrin activation. Furthermore, DKO platelets also
failed to activate the small GTPase Rap2 in response to Cvx treatment (Supplemental Figure
2, available online at http://atvb.ahajournals.org), demonstrating that all Rap signaling in
platelets is under the control of CalDAG-GEFI and P2Y12.
To confirm the functional association between Rap1 and Rac1 in Cvx-stimulated platelets,
we compared the platelet activation response of DKO platelets to that of WT platelets
treated with the small molecule inhibitor EHT 1864 (WT/EHT). Previous studies have
shown that EHT 1864 specifically blocks Rac, but not RhoA and Cdc42, activation in vitro
and in vivo.34,35 In platelets, EHT 1864 inhibited Rac1 activation downstream of ITAM-
coupled receptors17 at a dosage of 100 μmol/L (Supplemental Figure 3, available online at
http://atvb.ahajournals.org). Both WT/EHT and DKO platelets showed impaired spreading
on a fibrinogen surface after stimulation with Cvx (Figure 2A and 2B). Shape change and
the formation of filopodia and lamellipodia was observed in WT platelets as early as 3
minutes after addition of Cvx. Lamellipodia formation progressed continuously, leading to a
more than doubling of the platelet surface area within 30 minutes of activation. In contrast,
DKO or WT/EHT platelets underwent shape change and filopodia formation but failed to
form lamellipodia. Consequently, their platelet surface area did not markedly increase.
Importantly, we did not observe any difference in platelet surface area between DKO, WT/
EHT, and DKO/EHT platelets, suggesting that both Rap1 and Rac1 are crucial for
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lamellipodia formation and spreading in Cvx-activated platelets. Rac1 has also been
implicated in clot retraction, another actin-based mechanism initiated by integrin outside-in
signaling. We could confirm this finding in WT/EHT platelets, where clot retraction was
significantly delayed when compared to WT controls (Figure 2C, D). Importantly, however,
impaired Rap1 signaling (DKO platelets) had a significantly stronger inhibitory effect on
clot retraction than inhibition of Rac1, possibly because of the direct role of Rap1 in integrin
activation.
Next, we evaluated the ability of DKO and WT/EHT platelets to release their granules
(Figure 3). Consistent with recent studies,16 Cvx-induced release of α granules was
markedly impaired in WT/EHT platelets, in particular in response to low and medium doses
of the agonist (Figure 3A). At the highest tested concentration of Cvx, however, α granule
release in WT/EHT platelets was significantly reduced but not abolished when compared to
that of WT platelets. In comparison, α granule release was completely abolished in DKO
platelets at all agonist concentrations tested (10-fold the EC50 for Cvx). Pretreatment with
EHT 1864 did not affect secretion in Cvx-stimulated DKO platelets. Rap1 and Rac1
signaling contributed in a similar fashion to dense granule release (Figure 3B). Inhibition of
Rac1 signaling by EHT 1864 abolished dense granule release at low/medium but not high
doses of Cvx, whereas virtually complete inhibition of dense granule release was observed
in DKO platelets at all agonist concentrations tested.
In contrast to spreading, clot retraction and granule release, WT/EHT, and DKO platelets
did not contribute in a similar way to PLCγ2-mediated calcium (Ca2+) mobilization in Cvx-
stimulated platelets (Figure 4A, B). Compared to WT controls, Ca2+ store release in WT/
EHT platelets was reduced by ≈50%, both at low and high doses of the agonist. Ca2+ flux
observed in DKO platelets, however, was not significantly different to that in WT cells.
Similar results were obtained on stimulation of platelets with an alternative GPVI-specific
agonist, collagen-related peptide (CRP) (Supplemental Figure 4, available online at
http://atvb.ahajournals.org), suggesting that in GPVI-stimulated platelets both Rap1 and
Rac1 signaling contribute to spreading and granule release, but Rac1 alone participates in
PLCγ2 activation and subsequent Ca2+ mobilization. One potential explanation for this
finding is that the activation of Rac1 immediately downstream of the agonist receptor occurs
independent of Rap1. Our studies confirm this hypothesis, as we observed that at t=10
seconds after Cvx stimulation Rac1 activation in DKO platelets was comparable to that of
WT cells, whereas Rap1 activation was completely abolished. At later time points, however,
Rac1-GTP–levels in WT platelets increase and reach a plateau after t=1 minute, while a
sharp decrease in Rac1 activation was observed in the DKO platelets (Figure 4C and 4D).
Similarly, results were observed using a quantitative ELISA-like approach (Supplemental
Figure 5, available online at http://atvb.ahajournals.org).
In our previous work, we demonstrated that Rap1 activation in platelets depends on
independent yet synergistic signaling by Ca2+/CalDAG-GEFI and ADP/P2Y12.22–24 While
signaling by Ca2+/CalDAG-GEFI mediates the rapid but reversible activation of Rap1,
signaling by ADP/P2Y12 is crucial for the sustained activation of the small GTPase.
Consistent with the effect of Rac1 inhibition on calcium mobilization (Figure 4) and granule
release (Figure 3), we observed that pretreatment of WT platelets with EHT 1864 impaired
both pathways leading to Rap1 activation. Compared to WT controls, Rap1 activation in
WT/EHT platelets activated with high-dose Cvx was markedly reduced at both early (t=30″)
and late (t=600″) time points (Figure 5A). However, it was not completely abolished and the
residual activation was sufficient to facilitate αIIbβ3 activation and platelet aggregation
(Figure 5B–5D).
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Our studies establish a central role for Rap1-Rac1 signaling circuits in platelet activation
(Figure 6). Downstream of the collagen receptor, GPVI, 1 pool of Rac1 is activated
immediately and contributes to PLCγ2-mediated mobilization of intracellular calcium
([Ca2+]i). Increased [Ca2+]i triggers CalDAG-GEFI–mediated Rap1 activation, which is
crucial for the activation of a second pool of Rac1. Sustained Rac1 activation is required for
actin-dependent platelet responses such as spreading and granule release. In turn, ADP
released from dense granules induces sustained activation of Rap1 via engagement of
P2Y12. Thus, a continuous crosstalk between the small GTPases, Rac1 and Rap1, is
required for optimal platelet activation downstream of the collagen receptor GPVI.
Using inhibitors to P2Y12 in combination with CalDAG-GEFI–/– platelets, we have
recently demonstrated that (1) each pathway independently contributes to Rap1 activation in
activated platelets, and (2) Rap1 activation is virtually abolished in P2Y12 inhibitor-treated
CalDAG-GEFI–/– platelets.22–24 To rule out reported off-target effects of P2Y12 inhibitors
in our studies,33 we here used platelets isolated from mice deficient for both CalDAG-GEFI
and P2Y12 (DKO). So far, our limited breeding efforts of DKO mice from crosses of mice
heterozygous for both CalDAG-GEFI and P2Y12 did not reveal increased embryonic
lethality of DKO pups (not shown). This finding is in contrast to the 85% embryonic and
perinatal lethality reported in Rap1B–/– mice.21 However, although Rap1 is widely
expressed, both CalDAG-GEFI36 and P2Y1237 show a much more restricted expression
profile. Thus, it appears likely that the increased lethality observed in Rap1B–/– mice is
caused by impaired function of a cell type other than platelets. In addition to viability,
peripheral platelet counts and platelet size in DKO mice were comparable to WT controls
(not shown). However, Rap1 activation and integrin-mediated aggregation were abolished in
the Cvx-stimulated DKO platelets (Figure 1 and 5), confirming our recent studies with
P2Y12 inhibitors.22,23
We are aware that DKO platelets may have defects that are independent of Rap1 signaling.
A prominent consequence of P2Y12 engagement is inhibition of adenylyl cylcase via Gαi.37
Several studies, however, have documented that there is no causal relationship between
adenylyl cyclase inhibition and platelet aggregation.38,39 P2Y12 also leads to the activation
of PI3 kinase signaling. At least part of the PI3 kinase-driven response, however, is
mediated via activation of Rap1.40,41 The serine/threonine protein kinase B/Akt is another
effector of PI3 kinase. It is currently not clear if Akt and Rap1 are part of the same signaling
pathway or if they operate independent of each other. Although previous works have shown
that Rac1 activation is dependent on an increase in [Ca2+]i and potentiated by signaling via
P2Y12,29,30 the mechanism(s) by which Ca2+ and P2Y12 modulate this molecule are
unknown. Our results suggest that both Ca2+-and P2Y12-dependent Rac signaling is
mediated by Rap1, as (1) we observed a strong correlation between the activation kinetics of
Rap1 and Rac1 in stimulated platelets (Figure 1); (2) sustained, but not early, Rac1
activation is abolished in DKO platelets (Figure 4C, D); (c) Rap1 and Rac1 mediate similar
cellular responses such as spreading, clot retraction, and granule release (Figure 2 and 3),
and (4) the GEF activity of CalDAG-GEFI is directed toward Rap but not Rac GTPases.36
Unfortunately, Rac1 activation has not been examined in platelets from Rap1B–/– mice. A
very recent study on platelet function in Rap1B–/– mice, however, shows a role of Rap1B in
granule secretion, spreading on fibrinogen and clot retraction, but not in calcium
mobilization.42 Thus, Rap1B–/– platelets show defects in Rac1-dependent platelet
responses, supporting our conclusion of a crosstalk between the 2 small GTPases. The defect
in secretion of the Rap1B–/– platelets is less severe than that observed in platelets deficient
in CalDAG-GEFI and P2Y12. To us the most likely explanation for this difference is
provided by back-up signaling in Rap1B–/– platelets via Rap2, which was shown to
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associate with granules in human neutrophils.43 Confirming this hypothesis, we here provide
first evidence that CalDAG-GEFI mediates Rap2 activation in Cvx-activated platelets and
that simultaneous deficiency of CalDAG-GEFI and P2Y12 prevents the generation of Rap2-
GTP (Supplemental Figure 2).
Recent studies in transgenic mice identified a key role for Rac1 in various platelet
responses.11–13,16 In our study we blocked Rac1 activation with EHT 1864, an inhibitor that
directly binds Rac, displaces the nucleotide and inhibits further GTP loading.35 Thus, EHT
1864 inhibits Rac activation independent of which Rac-GEF catalyzes the GDP-GTP
exchange, a clear advantage over other Rac inhibitors that target the function of individual
Rac-GEFs.44 Characterization studies in vitro and in cell types other than platelets have
shown that EHT 1864 specifically inhibits all known Rac isoforms (Rac1>Rac2≫Rac3), but
not other Rho GTPases such as Cdc42 and RhoA.35 In platelets stimulated via ITAM-
coupled receptors, EHT 1864 completely prevents the activation of Rac1,17 the only Rac
isoform expressed at detectable levels in these cells.11 Moreover, WT platelets treated with
EHT 1864 and platelets isolated from Rac1–/– mice11–13,16 show very similar defects in the
platelet activation response, suggesting that neither RhoA nor Cdc42-activation are affected
by this compound. Using EHT 1864-treated WT platelets as a control for impaired Rac1
signaling, we here provide the first evidence for Rap1-dependent and -independent pools of
Rac1 in platelets (Figure 4C). Although the Rap1-independent pool of Rac1 is critical for
Ca2+ mobilization in platelets, Rap1-dependent Rac1 signaling controls spreading, clot
retraction, and granule release. Rac1 activation independent of Rap1 is consistent with
studies in lymphocytes, where the Rac-GEF Vav is activated directly by tyrosine kinases
and mediates Rac-dependent PLCγ activation downstream of ITAM-coupled receptors.45 In
platelets, the Vav1 and Vav3 isoforms have been implicated in GPVI-dependent PLCγ2
activation.46 It is currently not clear how Rap1 controls Rac1 in platelets or other cells, but it
has been reported that GTP-bound Rap1 can bind to at least 3 distinct Rho-family GEFs.
Studies in fibroblasts showed that Rap1 directly binds the RacGEFs Vav2 and Tiam1, and
that Rap1 is important for the translocation of the Rac-GEFs to the plasma membrane but
not the GTP-loading of Rac1.47 However, a more recent study in T cells demonstrates that
constitutively active Rap1 directly binds Tiam1 and enhances Rac1 GTP-loading.48 A
separate study further identified that binding of Rap1-GTP to STEF (Tiam2) is necessary for
STEF-dependent Rac1 activation in Chinese hamster ovary cells.49 Our studies show
markedly impaired Rac GTP-loading in DKO platelets, suggesting that GEF-mediated
activation of the small GTPase rather than the translocation of the GEFs may be responsible
for the observed crosstalk in platelets. It is also conceivable that active Rap inhibits a Rac-
guanine nucleotidase-activating proteins, which would lead to sustained Rac activity. To the
best of our knowledge, however, such an interaction has not been documented. Furthermore,
our results do not exclude the possibility that Rap affects Rac indirectly via a different
signaling pathway that feeds into Rac1 activation.
Although the spreading defect in DKO and WT/EHT platelets was very similar, we
observed interesting differences in granule release and calcium mobilization in these cells.
The release of both α- and dense-granules was virtually abolished in DKO platelets, whereas
significant granule release was observed in WT/EHT cells stimulated with high-dose Cvx
(Figure 3). In contrast, Cvx-induced Ca2+ mobilization from internal stores was reduced in
WT/EHT but not DKO platelets (Figure 4A and 4B). It is difficult to speculate why granule
release in the absence of Rap1 signaling is completely abolished, whereas inhibition of Rac1
or genetic deletion of Rac116 only partially blocks this response. One possibility is that
integrin outside-in signaling provides important feedback for granule release, and that this
process is more profoundly affected in DKO platelets. Supporting this hypothesis, we
observed a stronger contribution of Rap1 to clot retraction (Figure 2C and 2D), a cellular
response dependent on integrin outside-in signaling.50 Alternatively, Rap could be directly
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involved in granule release as it has been suggested based on its enrichment in granule
membranes.18,43 Further studies are required to address this point.
In conclusion, we show that Rap1-Rac1 circuits potentiate platelet activation downstream of
the collagen receptor, GPVI. While signaling via Rac1 affects both the early and the late
phase of Rap1 activation, active Rap1 is required for sustained but not immediate activation
of Rac1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Rap1 activation correlates with Rac1 activation in platelets. A, B, Time course of Rac1 (top
panel) and Rap1 (central panel) activation on stimulation of wild type (WT, black bars) or
CalDAG-GEFI–/– (CDI–/–, gray bars) platelets with 500 ng/mL convulxin (Cvx) in the
absence (solid pattern) or presence (striped pattern) of the P2Y12 inhibitor, 2-MesAMP (100
μmol/L, MesAMP). C, D, Time course of Rac1 and Rap1 activation on stimulation of WT
(black bars), CalDAG-GEFI–/– (gray bars), P2Y12–/– (white bars) or CalDAG-GEFI–/–
×P2Y12–/– (double knock-out [DKO], white/gray checkered bars) platelets with 500 ng/mL
convulxin. A, C, Representative images: the bottom panel shows total Rap1 as loading
control. B, D, Densitometric analysis of Rac1-GTP (left) and Rap1-GTP (right) shown as
percentage of maximal activation (mean±SD, n=3).
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Rap1 and Rac1 mediate platelet spreading and clot retraction. A, B, Spreading of convulxin-
activated platelets on fibrinogen-coated slides. A, Representative images captured with a
100 × oil objective. B, Surface area (μm2) of spreading platelets (mean±SD, n=100/
experiment; 3 independent experiments). C, D, Clot retraction. C, Representative images. D,
The extent of clot retraction expressed as percentage of serum extruded from the clot (mean
±SD, n=5). Platelet preparations studied: wild type (WT, black bar) and CalDAG-GEFI–/–
×P2Y12–/– (double knock-out [DKO], gray bar) in the absence (solid bar) or presence of
EHT 1864 (checkered bar). ***P<0.0001.
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Rap1 and Rac1 contribute to GPVI-mediated α- and dense-granule secretion. A, Dose
response of convulxin (Cvx)-induced α-granule secretion determined by flow cytometry
(binding of FITC-conjugated α-P-selectin antibody). Data shown are mean fluorescence
intensities (MFI)±SD (n=6). B, Dose response of Cvx-induced dense granule secretion
determined by 3H-serotonin release into platelet supernatants after 10 minutes of stimulation
(mean±SD; n=6 in 3 independent experiments), *P<0.05, **P<0.01, ***P<0.001. Platelet
preparations studied: wild type (WT, black line) and CalDAG-GEFI–/–×P2Y12–/– (double
knock-out [DKO], gray line), in the absence (solid line) or presence (discontinued line) of
100 μmol/L EHT 1864.
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A distinct pool of Rac1 is activated independently of Rap1 signaling immediately after
GPVI stimulation. A, Calcium store release of wild type (WT, black) and CalDAG-GEFI–/–
×P2Y12–/– (double knock-out [DKO], gray) platelets, in the absence (solid line and bar) or
presence (discontinued line, checkered bar) of 100 μmol/L EHT 1864, stimulated with high
(left: 1 μg/mL, HD CVX) or low (right: 0.2 μg/mL, LD CVX) dose convulxin (Cvx). B,
Results expressed as the percentage of maximal Fluo-4 fluorescence intensity±SD measured
in the indicated platelet preparations, n=6; **P<0.01, ***P<0.001. C, D, Time course of
Rac1 (top panel) and Rap1 (central panel) activation in WT (black line) and CalDAG-
GEFI–/–×P2Y12–/– (DKO, gray line) platelets. C, Representative images; the bottom panel
shows total Rap1 as loading control. D, Densitometric analysis of Rac1-GTP levels shown
as percentage of maximal activation (mean±SD, n=3), *P<0.05.
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Rac1 signaling provides feedback for Rap1 and integrin activation in GPVI-stimulated
platelets. A, Time course of Rap1 activation (upper panel) in platelets stimulated with 250
ng/mL convulxin (Cvx)in the absence (wild type [WT]) or presence of 100 μmol/L EHT
1864 (WT/EHT); representative of 3 independent experiments. The lower panel shows total
Rap1 as loading control. B, Flow cytometric determination of αIIbβ3 integrin activation
(binding of PE-conjugated Jon/A antibody) in Cvx-stimulated platelets (WT: black, double
knock-out [DKO]: gray, WT/EHT: checkered black, DKO/EHT: checkered gray). Data
shown are mean fluorescence intensities (MFI)±SD, n=6; *P<0.05, **P<0.01, ***P<0.001.
C, D, Platelet aggregation of WT platelets in the absence (WT, solid line) or presence of 100
μmol/L EHT 1864 (WT/EHT, discontinued line). C, Representative aggregation traces
(CalDAG-GEFI–/–×P2Y12–/– (DKO) aggregation in response to 250 ng/mL of Cvx is
shown for comparison, gray traces). D, Percentage of platelet aggregation determined at t=5
minutes after addition of the agonist (mean±SD, n=3).
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Schematic representation of the crosstalk between Rac1 and Rap1 in GPVI-stimulated
platelets. Two distinct pools of Rac1 control (1) phospholipase Cγ2 (PLCγ2)-dependent
calcium (Ca2+) flux (rectangle) and (2) actin dynamics involved in granule secretion,
spreading, and clot retraction (circle). Both Rac1 pools potentiate Rap1 activation by
amplifying the Ca2+/CalDAG-GEFI– and the secretion/P2Y12-dependent pathways,
respectively. In turn, Rap1 positively regulates only Rac1-dependent actin remodelling
(circle).
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